General Information of Disease (ID: DISF44L6)

Disease Name Systemic sclerosis
Synonyms
Scleroderma; systemic Scleroderma; diffuse Scleroderma; SSc, diffuse sclerosis; progressive systemic sclerosis; Systemic Scleroderma; systemic sclerosis; diffuse sclerosis; Scleroderma, diffuse; systemic scleroderma; SSc; PSS (progressive systemic sclerosis); Scleroderma, systemic; Scleroderma (& [systemic sclerosis]); Scleroderma syndrome
Disease Class 4A42: Systemic sclerosis
Definition
A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.
Disease Hierarchy
DISVQ342: Scleroderma
DIS9YPUQ: Dermatological disease
DISF44L6: Systemic sclerosis
ICD Code
ICD-11
ICD-11: 4A42
ICD-9
ICD-9: 710.1
Expand ICD-11
'4A42
Expand ICD-10
'M34; 'M34.2; 'M34.9
Expand ICD-9
710.1
Disease Identifiers
MONDO ID
MONDO_0005100
MESH ID
D012595
UMLS CUI
C0036421
MedGen ID
19897
Orphanet ID
90291
SNOMED CT ID
89155008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 5 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Alemtuzumab DMZL3IV Approved Antibody [1]
Busulfan DMXYJ9C Approved Small molecular drug [2]
Fludarabine DMVRLT7 Approved Small molecular drug [3]
Iloprost DMVPZBE Approved Small molecular drug [4]
Pomalidomide DMTGBAX Approved Small molecular drug [5]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 12 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CPL-7075 DM62E7C Phase 3 Small molecular drug [6]
Resveratrol DM3RWXL Phase 3 Small molecular drug [6]
ACER-003 DMXXUMS Phase 2 NA [6]
ARG201 DM3XQLD Phase 2 NA [6]
EHP-101 DMDGCFC Phase 2 Small molecule [7]
GSK2330811 DMB0CXT Phase 2 NA [8]
SAR-100842 DMDMQW0 Phase 2 NA [6]
SAR-156597 DMUICJD Phase 2 Antibody [8]
Vasculan DM33IOC Phase 2 NA [8]
ACE-1334 DMF1OUP Phase 1 Protein [9]
CC-10015 DM9VSBV Phase 1 NA [10]
VI7734 DMWKFRC Phase 1 NA [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 167 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ADAM8 TTQWYMD Limited Altered Expression [11]
ADAMTS13 TTUREBK Limited Altered Expression [12]
AIF1 TT12MEP Limited Biomarker [13]
AQP3 TTLDNMQ Limited Altered Expression [14]
BCL6 TTC9YX5 Limited Altered Expression [15]
CTLA4 TTI2S1D Limited Altered Expression [16]
CXCL10 TTQOVYA Limited Biomarker [17]
EGFL7 TT7WD0H Limited Altered Expression [18]
FGF23 TT2IZ4K Limited Biomarker [19]
FOSL2 TT689IR Limited Biomarker [20]
HDAC5 TTUELN5 Limited Biomarker [21]
HLA-DQA1 TTU2I3J Limited Genetic Variation [22]
IL13RA1 TTNEAMG Limited Biomarker [23]
IL16 TTW4R0B Limited Altered Expression [24]
IL17F TT2B6PS Limited Biomarker [25]
IL1R1 TTWOTEA Limited Biomarker [26]
IL21R TTZO9B0 Limited Biomarker [27]
IL22 TTLDX4N Limited Biomarker [15]
IRF8 TTHUBNK Limited Genetic Variation [28]
ITGA5 TTHIZP9 Limited Altered Expression [29]
KIR2DL2 TTU0P73 Limited Biomarker [30]
KIR3DL2 TTQH3N0 Limited Genetic Variation [31]
KLK1 TT5T3P6 Limited Altered Expression [32]
MCAM TTHRE05 Limited Biomarker [33]
PDE5A TTJ0IQB Limited Genetic Variation [34]
PDGFA TTSM78N Limited Biomarker [35]
PLAUR TTNOSTX Limited Altered Expression [36]
PRTN3 TT5MLC4 Limited Biomarker [37]
S1PR5 TTDZCKV Limited Biomarker [38]
SDC2 TT5H2F0 Limited Biomarker [39]
SERPINH1 TTPSWQG Limited Biomarker [40]
SPARC TTBQFM7 Limited Altered Expression [41]
TAGLN TTDRZ9H Limited Altered Expression [42]
TAP1 TT7JZI8 Limited Genetic Variation [43]
TBX21 TTNF9PH Limited Genetic Variation [44]
TLR7 TTRJ1K4 Limited Altered Expression [45]
TNNC1 TT8RDXP Limited Altered Expression [46]
BLK TTNDSC3 moderate Genetic Variation [47]
CCR8 TTE836A moderate Altered Expression [48]
CEL TTTRNQW moderate Biomarker [49]
PAH TTGSVH2 moderate Biomarker [50]
TNFAIP3 TT5W0IO moderate Genetic Variation [51]
ACR TTAHE2N Strong Biomarker [52]
AGER TTMO9HF Strong Genetic Variation [53]
ALDH3A2 TTB6UM0 Strong Genetic Variation [54]
ALOX5AP TTDMBF5 Strong Genetic Variation [55]
APLNR TTJ8E43 Strong Biomarker [56]
APOH TT2OUI9 Strong Biomarker [57]
BPI TTXCSDR Strong Altered Expression [58]
BST2 TT90BJT Strong Altered Expression [59]
CBL TT7QT13 Strong Altered Expression [60]
CCN1 TTPK79J Strong Biomarker [21]
CD1A TTBGTFN Strong Biomarker [61]
CD248 TTYJWT7 Strong Altered Expression [62]
CD28 TTQ13FT Strong Altered Expression [63]
CD69 TTPQE9F Strong Altered Expression [27]
CD70 TTNCIE0 Strong Altered Expression [64]
CDH11 TTRGWZC Strong Biomarker [65]
CDH5 TTXLCFO Strong Biomarker [66]
CENPE TTZD5QR Strong Biomarker [67]
CHRM5 TTH18TF Strong Genetic Variation [68]
CHRNA9 TTQACP9 Strong Genetic Variation [69]
COL1A2 TTUABC1 Strong Biomarker [70]
CSF1 TT0IQER Strong Biomarker [71]
CSK TTX6F0Q Strong Genetic Variation [72]
CTSG TTQAJF1 Strong Altered Expression [58]
CTSV TTSD9T1 Strong Altered Expression [73]
CXCL13 TT0NIZ1 Strong Altered Expression [74]
CYP21A2 TTP4GLG Strong Genetic Variation [53]
DCN TTB3XAN Strong Altered Expression [75]
DDR2 TTU98HG Strong Altered Expression [76]
ENG TTB30LE Strong Genetic Variation [77]
ENPP2 TTSCIM2 Strong Biomarker [78]
EPHA1 TTLFZVU Strong Biomarker [79]
FCGR2B TT5RWKQ Strong Altered Expression [80]
FCGR3A TTIFOC0 Strong Biomarker [81]
FKBP1A TTMW94E Strong Biomarker [82]
FOLR2 TTT54CI Strong Altered Expression [83]
GDF15 TT4MXVG Strong Biomarker [84]
GEM TTAZF9M Strong Biomarker [85]
GPI TT19JIZ Strong Biomarker [86]
GRB2 TTEYRJ9 Strong Genetic Variation [68]
HAX1 TT21BYA Strong Altered Expression [87]
HDC TTV9GOF Strong Altered Expression [88]
HHAT TT1VNCG Strong Altered Expression [89]
HLA-DQB2 TTL7VOU Strong Genetic Variation [53]
HLA-G TTLKFB3 Strong Altered Expression [90]
HSP90AB1 TTH5YN2 Strong Altered Expression [91]
ICOS TTE5VP6 Strong Biomarker [92]
ICOSLG TTB9Z8R Strong Genetic Variation [93]
ID2 TTW8A5N Strong Genetic Variation [94]
IFNAR1 TTSYFMA Strong Biomarker [95]
IFNAR2 TTMQB37 Strong Biomarker [96]
IFNL1 TTM624L Strong Altered Expression [97]
IFNL3 TTRF4Q2 Strong Genetic Variation [98]
IGFBP3 TTZHNQA Strong Altered Expression [46]
IKZF2 TTKT5NV Strong Genetic Variation [47]
IL10RB TTJTRMK Strong Biomarker [99]
IL12RB2 TT4SWR8 Strong Genetic Variation [100]
IL13RA2 TTMPZ7V Strong Genetic Variation [101]
IL19 TT87RWS Strong Genetic Variation [102]
IL1RAP TTWS50K Strong Biomarker [26]
IL21 TT9QEJ6 Strong Biomarker [15]
IL23A TTC1GLB Strong Altered Expression [103]
ITGB8 TTIF29E Strong Biomarker [104]
KIR2DL3 TTEX3SI Strong Biomarker [31]
KIR2DS1 TTVWAGF Strong Genetic Variation [31]
KIR2DS2 TTV3CFI Strong Biomarker [30]
LIFR TTID542 Strong Altered Expression [105]
LTB4R TTN53ZF Strong Biomarker [106]
MFGE8 TT1GLAJ Strong Altered Expression [107]
MMP12 TTXZ0KQ Strong Biomarker [108]
MMP21 TTYRF5E Strong Biomarker [109]
MSR1 TT2TDH9 Strong Altered Expression [71]
MUC1 TTBHFYQ Strong Altered Expression [110]
NCF1 TTZ4JC3 Strong Genetic Variation [111]
NFKB1 TTUIZKC Strong Genetic Variation [112]
NR0B1 TTTK36V Strong Biomarker [113]
OSMR TTAH0KM Strong Biomarker [23]
PAM TTF4ZPC Strong Altered Expression [114]
PGGT1B TTX20QP Strong Altered Expression [115]
PLOD2 TT8MEUD Strong Altered Expression [116]
POSTN TT8ALTZ Strong Altered Expression [117]
PRKG1 TT7IZSA Strong Altered Expression [118]
PTGIR TTOFYT1 Strong Biomarker [119]
PTP4A1 TTA8GFO Strong Altered Expression [120]
ROBO4 TT3S9TY Strong Altered Expression [121]
RORC TTGV6LY Strong Biomarker [122]
RXFP1 TTMAHD1 Strong Genetic Variation [123]
RXRB TTKLV96 Strong Biomarker [124]
SCGB1A1 TTONPVW Strong Biomarker [125]
SCN9A TT4G2JS Strong Genetic Variation [126]
SELE TT1PL7M Strong Biomarker [127]
SELL TT2IYXF Strong Posttranslational Modification [128]
SELP TTE5VG0 Strong Altered Expression [129]
SEMA4D TT5UT28 Strong Altered Expression [130]
SFTPD TTGLMU7 Strong Biomarker [131]
SHCBP1 TTZ9WGL Strong Altered Expression [114]
SIRT1 TTUF2HO Strong Biomarker [132]
SLC25A1 TTTD730 Strong Biomarker [133]
SLC33A1 TTL69WB Strong Biomarker [134]
SLC38A1 TT1YE9Z Strong Biomarker [135]
SLC47A1 TTMHCGA Strong Altered Expression [136]
SMAD7 TT0J32Z Strong Biomarker [137]
SOX5 TTXHSZK Strong Genetic Variation [138]
SRPK2 TTCZEJ9 Strong Biomarker [139]
TNC TTUCPMY Strong Biomarker [140]
TNFRSF14 TTWGTC1 Strong Biomarker [141]
TNFSF14 TTKVENM Strong Biomarker [141]
TNFSF4 TTBW580 Strong Altered Expression [142]
TRB TT84HCW Strong Genetic Variation [143]
TRPC1 TTA76X0 Strong Biomarker [144]
TRPM3 TTO3TD8 Strong Genetic Variation [145]
TRPM5 TT1N8F3 Strong Genetic Variation [145]
TSLP TTHMW3T Strong Biomarker [146]
TSSK2 TTA3Z2W Strong Biomarker [147]
TUSC2 TTJ8O14 Strong Biomarker [148]
TYK2 TTBYWP2 Strong Genetic Variation [100]
UTS2 TTERU0T Strong Genetic Variation [149]
VWF TT3SZBT Strong Altered Expression [12]
WRN TT2H5WQ Strong Altered Expression [150]
ACKR1 TTKY2NS Definitive Altered Expression [151]
F8 TT1290U Definitive Altered Expression [152]
IGFBP5 TTDWEA8 Definitive Biomarker [153]
ITGAM TTB69FJ Definitive Genetic Variation [68]
NOTCH4 TTXDIK2 Definitive Genetic Variation [154]
VIPR2 TT4O5P0 Definitive Altered Expression [155]
------------------------------------------------------------------------------------
⏷ Show the Full List of 167 DTT(s)
This Disease Is Related to 3 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC27A5 DT0TQS3 moderate Biomarker [49]
SLC11A1 DT650XW Strong Biomarker [156]
ABCC6 DT582KR Definitive Genetic Variation [157]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
SCLY DEH4TD6 moderate Genetic Variation [158]
GGCT DEKW6PB Strong Genetic Variation [159]
PGM1 DEA3VM1 Strong Biomarker [160]
------------------------------------------------------------------------------------
This Disease Is Related to 266 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ATP8B4 OT48TSYO Limited Genetic Variation [161]
BLM OTEJOAJX Limited Biomarker [162]
CCL7 OTDIS99H Limited Biomarker [163]
CENPA OT0NEJ4X Limited Altered Expression [164]
COMP OTS2FPMI Limited Altered Expression [165]
FBRS OTUVH446 Limited Biomarker [166]
FCN2 OTTHJBKZ Limited Altered Expression [167]
GTF2I OTUYL1TQ Limited Genetic Variation [168]
HLA-C OTV38BUJ Limited Biomarker [124]
HLA-DPB1 OTW8JHU2 Limited Genetic Variation [124]
HLA-DRB5 OTUX5TWM Limited Genetic Variation [169]
IKBKG OTNWJWSD Limited Altered Expression [170]
KLF5 OT1ABI9N Limited Biomarker [171]
LGALS9 OT7MF91K Limited Altered Expression [172]
LRPPRC OTXSK5LP Limited Altered Expression [105]
P4HB OTTYNYPF Limited Biomarker [173]
PI3 OT47MTC3 Limited Altered Expression [174]
PLD4 OT5I74II Limited Biomarker [175]
POLR3A OT5MSK10 Limited Biomarker [176]
RARRES2 OT1BJE8K Limited Biomarker [177]
RO60 OTLGM5A8 Limited Altered Expression [178]
S100A7 OTJFVJRF Limited Altered Expression [179]
SEMA4A OT8901H3 Limited Biomarker [180]
SERPINF2 OTZGAF8B Limited Biomarker [181]
SMOC1 OTJG2JQY Limited Biomarker [182]
SRY OT516T6D Limited Biomarker [183]
TAP2 OTWSYFI7 Limited Genetic Variation [43]
AIRE OTA7G1Y1 moderate Genetic Variation [184]
CENPC OTVJ6VE9 moderate Biomarker [185]
DDX19A OTBTDR44 moderate Biomarker [186]
DDX46 OTB2X9TO moderate Biomarker [186]
DHX16 OTW8KZAU moderate Biomarker [186]
GZMA OT43R33L moderate Altered Expression [187]
KRT7 OTLT3JFN moderate Genetic Variation [158]
MYBL2 OTZ3JX8Q moderate Altered Expression [188]
PARP9 OT7K4494 moderate Biomarker [49]
PSORS1C1 OT9HK436 moderate Biomarker [189]
RTCA OTSJRVTD moderate Biomarker [190]
SERPINE2 OTYF5340 moderate Genetic Variation [126]
TAL1 OTX4K6QZ moderate Genetic Variation [158]
ACOT7 OT7C68YV Strong Altered Expression [191]
ACSBG1 OTM040MW Strong Altered Expression [192]
ACTA2 OTEDLG8E Strong Biomarker [70]
ACTBL2 OTD6B81U Strong Altered Expression [191]
ANKS1A OTYZP3MP Strong Genetic Variation [68]
APOBEC3A OTYO6F5P Strong Genetic Variation [22]
ARHGAP31 OTUYTF4I Strong Genetic Variation [72]
ARHGEF5 OTUVGFT9 Strong Biomarker [193]
ASAP1 OT4DLRYY Strong Biomarker [148]
ASAP2 OTGEXULW Strong Biomarker [148]
ATG5 OT4T5SMS Strong Genetic Variation [100]
AVEN OTGIN5YK Strong Genetic Variation [68]
BANK1 OTXAAA11 Strong Biomarker [194]
BICD2 OTVJ03NZ Strong Biomarker [164]
CAPG OTJ86KI6 Strong Biomarker [195]
CARD16 OT4NUHWB Strong Biomarker [196]
CARMIL1 OT1A5IX5 Strong Altered Expression [197]
CAST OTBXZZGF Strong Genetic Variation [198]
CBX5 OT8VYY84 Strong Biomarker [199]
CCL18 OT7JYSK9 Strong Altered Expression [200]
CCL19 OTQ2UJMH Strong Altered Expression [201]
CCL24 OT9LGHV0 Strong Altered Expression [202]
CCL25 OTLWJ8CJ Strong Biomarker [203]
CD72 OTPOJID2 Strong Altered Expression [130]
CDCA5 OTZLCQ5U Strong Altered Expression [204]
CDHR5 OTTBWQMN Strong Genetic Variation [72]
CDK2AP2 OTR99SJ8 Strong Altered Expression [205]
CDSN OTQW4HV6 Strong Genetic Variation [206]
CEBPZ OT11BATG Strong Biomarker [188]
CENPB OT3N73QR Strong Biomarker [207]
CHI3L1 OT2Z7VJH Strong Biomarker [208]
CHST8 OTQT4TKR Strong Genetic Variation [209]
COL1A1 OTI31178 Strong Altered Expression [18]
COL3A1 OTT1EMLM Strong Biomarker [210]
COPB2 OT82JIGC Strong Biomarker [196]
CRYGD OTW29JC4 Strong Biomarker [211]
CSAD OT3I2G0A Strong Altered Expression [212]
CXCL14 OTM189TA Strong Altered Expression [213]
CXCL6 OTFTCQ4O Strong Biomarker [214]
CYBA OT16N9ZO Strong Genetic Variation [215]
CYCS OTBFALJD Strong Biomarker [216]
DDX6 OTKWXVDY Strong Genetic Variation [72]
DECR1 OTCDIR6X Strong Genetic Variation [217]
DGKQ OT8OEPYT Strong Genetic Variation [100]
DLAT OT9LBJVN Strong Altered Expression [218]
DOK5 OT2XWUPN Strong Biomarker [219]
DSG2 OTJPB2TO Strong Biomarker [104]
DUOX1 OTQ2AEW0 Strong Altered Expression [220]
EFEMP2 OT0I2B4J Strong Biomarker [221]
EGR2 OTAVQ78J Strong Altered Expression [222]
EGR3 OTGPJIRA Strong Altered Expression [223]
EIF2B1 OT4NCVY1 Strong Biomarker [224]
EIF2B2 OTQQMHM1 Strong Biomarker [224]
EIF2B4 OTTM5SX1 Strong Biomarker [224]
EIF2B5 OTV3R4RB Strong Genetic Variation [225]
EIF2S2 OTXF0B09 Strong Biomarker [224]
EMG1 OTFDX7HY Strong Biomarker [226]
ERAL1 OTSH78HD Strong Genetic Variation [227]
ESYT1 OTA8NSJF Strong Genetic Variation [138]
EXOSC10 OTH8Z0AL Strong Biomarker [228]
FAM167A OT9JF3JQ Strong Genetic Variation [229]
FAM20A OT5Z5IW8 Strong Biomarker [230]
FBL OTRODIE5 Strong Biomarker [231]
FCN3 OTPRENLS Strong Biomarker [232]
FCRL6 OTLIXQMQ Strong Biomarker [11]
FGF6 OTRJ679P Strong Altered Expression [233]
FHL5 OT6C00Z1 Strong Altered Expression [191]
FLI1 OT0EV3LX Strong Biomarker [234]
FLII OT7G9JG6 Strong Altered Expression [235]
FSTL1 OT6KEZUD Strong Biomarker [236]
GAB1 OTQKE6V4 Strong Altered Expression [237]
GCHFR OTEOT8GI Strong Altered Expression [204]
GRB10 OTCKXGRC Strong Genetic Variation [138]
GSDMA OT912R2E Strong Genetic Variation [238]
GSDMB OTWA7P10 Strong Genetic Variation [72]
GYPA OTABU4YV Strong Genetic Variation [239]
HFM1 OTHV3EFE Strong Biomarker [240]
HLA-DMB OT17HGXJ Strong Biomarker [241]
HLA-DPA1 OT7OG7Y2 Strong Genetic Variation [138]
HLA-DQB1 OTVVI3UI Strong Genetic Variation [242]
HLA-DRA OT7KZMP2 Strong Genetic Variation [138]
HSPA1L OTC2V1K6 Strong Genetic Variation [53]
ICAM2 OT3E070F Strong Biomarker [243]
IFI16 OT4SPU0U Strong Biomarker [244]
IFIT1 OTXOQDSG Strong Altered Expression [28]
IFNA1 OTPMKY0L Strong Altered Expression [245]
IFT122 OTSK3OAD Strong Biomarker [246]
IL12RB1 OTM1IJO2 Strong Genetic Variation [72]
IL17B OTS86H50 Strong Biomarker [25]
IL17RA OTVVI8ER Strong Altered Expression [247]
IL1F10 OTJAASGC Strong Biomarker [248]
IL26 OT2WYCW4 Strong Altered Expression [247]
IL34 OTZ15VVK Strong Altered Expression [249]
IL6ST OT1N9C70 Strong Altered Expression [105]
INTS4 OT5JQ913 Strong Genetic Variation [156]
IRF5 OT8SIIAP Strong Altered Expression [250]
IRF7 OTC1A2PQ Strong Biomarker [251]
ITGB5 OT21MF51 Strong Biomarker [252]
JAZF1 OTXTYSYD Strong Genetic Variation [68]
KIAA0319L OTZ5X6IM Strong Genetic Variation [68]
KIR2DL5B OTSV0JL9 Strong Biomarker [31]
KIR2DS3 OT3PSLDL Strong Biomarker [31]
KIR3DL1 OTPOSXFX Strong Biomarker [85]
KLK12 OTNYK59J Strong Biomarker [253]
KRT1 OTIOJWA4 Strong Biomarker [254]
LAMTOR2 OTHEDISB Strong Altered Expression [205]
LGALS7 OTMSVI7R Strong Altered Expression [255]
LIAS OTOSW67J Strong Biomarker [256]
LOXL4 OT6XY2JL Strong Biomarker [257]
LRIT1 OTNEQPMZ Strong Altered Expression [114]
LRMDA OTIPNKTU Strong Genetic Variation [68]
LRRC34 OTSPZLKF Strong Genetic Variation [258]
LTBP4 OTC8WL2V Strong Altered Expression [259]
MAGI2 OTXDDKZS Strong Biomarker [260]
MBD1 OTD19VO6 Strong Biomarker [261]
MBD4 OTWR9YXE Strong Biomarker [262]
MMD OTB5I4OC Strong Biomarker [263]
MMP23B OT2OR6TS Strong Biomarker [109]
MMRN1 OT7ZNYHT Strong Biomarker [191]
MNAT1 OTXLOYCB Strong Altered Expression [204]
MPZ OTAR2YXH Strong Biomarker [113]
MRPS30 OTDXIAGG Strong Biomarker [148]
MRTFA OTCVXASM Strong Biomarker [264]
MSH5 OTDARQT3 Strong Genetic Variation [53]
MSN OTZJ4J6G Strong Altered Expression [265]
MT3 OTVCZ7HI Strong Biomarker [266]
MTPAP OT6HQ02S Strong Biomarker [148]
MX1 OT6X8G5T Strong Altered Expression [96]
MYBPH OTQJBPUR Strong Biomarker [191]
NAA16 OTWMA7LK Strong Biomarker [135]
NAB1 OTEWHIZR Strong Genetic Variation [72]
NANOS2 OTFM2IDJ Strong Biomarker [267]
NCF2 OTAUW7L2 Strong Genetic Variation [100]
NDN OTYBYJ82 Strong Altered Expression [268]
NECTIN2 OTIE0W6O Strong Biomarker [236]
NFIC OTLMCUIB Strong Biomarker [269]
NFIX OT1DPZAE Strong Biomarker [269]
NID2 OTHC33FF Strong Altered Expression [270]
NKX2-5 OTS1SAWM Strong Altered Expression [271]
NT5C1A OTS7UF36 Strong Biomarker [272]
NUP85 OTB5ZHC8 Strong Genetic Variation [72]
OAS2 OT64CCTM Strong Altered Expression [182]
OASL OTZ05YRP Strong Altered Expression [182]
OXCT1 OT536PE7 Strong Biomarker [273]
PAPOLA OTPHD65D Strong Biomarker [148]
PCBD1 OTDSRUD5 Strong Biomarker [274]
PCM1 OTFM133C Strong Biomarker [261]
PDAP1 OTJSWMOD Strong Biomarker [148]
PHF21A OTU3FFG4 Strong Biomarker [275]
PHRF1 OT21KEGX Strong Genetic Variation [68]
PIK3C2B OTY2PROB Strong Altered Expression [276]
PLAA OTZ7NJGA Strong Genetic Variation [277]
PLCL2 OTK5FDF6 Strong Biomarker [28]
PLD3 OTL07SP2 Strong Genetic Variation [175]
PMP22 OTXWYWCZ Strong Biomarker [113]
POLR1A OTDWI0TG Strong Biomarker [176]
POTEM OT7L2HGH Strong Altered Expression [191]
PRPF31 OTSJ0Z1Y Strong Biomarker [278]
PRR12 OTY2ILFT Strong Genetic Variation [100]
PSORS1C2 OTK43GE4 Strong Genetic Variation [279]
PTX3 OTPXHRKU Strong Altered Expression [280]
PXN OTVMMUOF Strong Altered Expression [265]
RAG2 OTG9UYTW Strong Biomarker [281]
RBFOX2 OTXY1WVH Strong Altered Expression [116]
RBM45 OTWTHD77 Strong Biomarker [282]
RETN OTW5Z1NH Strong Biomarker [283]
RGCC OTYJMLWM Strong Biomarker [284]
RHCE OTS18IZ5 Strong Biomarker [285]
RHOC OTOLE1FT Strong Genetic Variation [286]
RNPS1 OT7G4COD Strong Biomarker [139]
RPP14 OT4OYFSK Strong Altered Expression [205]
RPP38 OTOXHKTX Strong Biomarker [287]
RTRAF OTJ6NVMW Strong Genetic Variation [225]
SAMD9L OTKEJUCI Strong Genetic Variation [68]
SCAF1 OT16TM3N Strong Altered Expression [252]
SDHC OTC8G2MX Strong Biomarker [288]
SEMA3E OTD4S36H Strong Biomarker [289]
SF3B6 OTPRKS6S Strong Altered Expression [205]
SFTPB OTOHS07E Strong Genetic Variation [290]
SIGIRR OTNC3XFD Strong Biomarker [26]
SIGLEC1 OTNWSQA9 Strong Altered Expression [291]
SIRT7 OT5M4OT4 Strong Biomarker [292]
SMAD2 OTC6VB4K Strong Genetic Variation [293]
SMG1 OTTS3SXE Strong Biomarker [78]
SMG7 OTZDB0JX Strong Genetic Variation [100]
SNRNP70 OTP52YZ3 Strong Genetic Variation [294]
SPAAR OTWXG2R8 Strong Biomarker [295]
SPAG9 OT45AHMB Strong Altered Expression [296]
SPIN1 OT69VAOX Strong Genetic Variation [168]
SRF OTW18FQN Strong Biomarker [297]
ST3GAL1 OTFCO8QX Strong Altered Expression [298]
STAT4 OTAK3VFR Strong Genetic Variation [100]
STK19 OTYM6437 Strong Genetic Variation [53]
STN1 OT8UWRA3 Strong Genetic Variation [258]
SUV39H2 OTU0F4LL Strong Altered Expression [299]
SYS1 OTTVS1LN Strong Biomarker [300]
TAB1 OTPM6F85 Strong Altered Expression [301]
TAS2R13 OTSTOX5G Strong Biomarker [302]
TGFBI OTR443C5 Strong Biomarker [107]
TIMELESS OTD8DCBJ Strong Biomarker [193]
TIMP1 OTOXC51H Strong Biomarker [14]
TIMP4 OT8A68SW Strong Altered Expression [303]
TLR10 OTQ1KVJO Strong Altered Expression [304]
TNPO3 OTOT3HH0 Strong Genetic Variation [250]
TNXB OTVBWAV5 Strong Genetic Variation [53]
TREX1 OTQG7K12 Strong Genetic Variation [305]
TRIB3 OTG5OS7X Strong Biomarker [302]
TRIM21 OTA4UJCF Strong Altered Expression [178]
TSKU OT1XMRIM Strong Genetic Variation [107]
TSPY1 OTPY57X4 Strong Biomarker [306]
TSPY3 OTQK3AKI Strong Biomarker [306]
CDC42EP1 OTT525WA Definitive Biomarker [307]
CNTRL OTQI3VBA Definitive Biomarker [307]
CST4 OTXXM8EH Definitive Altered Expression [308]
DNAAF3 OT3OHO0O Definitive Biomarker [274]
DNAH5 OTC21RUS Definitive Biomarker [274]
DNAI1 OTF6C65Q Definitive Biomarker [274]
DNASE1L3 OTEUIMC2 Definitive Genetic Variation [100]
EDA OTAKS5WS Definitive Altered Expression [309]
FCRL4 OT3DVTRV Definitive Biomarker [310]
KLRB1 OTQ2959Y Definitive Biomarker [311]
PAK3 OT80M3BV Definitive Genetic Variation [157]
PXK OTSP1WLK Definitive Genetic Variation [72]
SSB OTCCTPBR Definitive Altered Expression [312]
SSNA1 OTWARAMR Definitive Biomarker [313]
TSSK1B OTRATM7R Definitive Biomarker [314]
------------------------------------------------------------------------------------
⏷ Show the Full List of 266 DOT(s)

References

1 Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. Arthritis Rheumatol. 2021 Sep;73(9):1720-1730.
2 Busulfan FDA Label
3 Fludarabine FDA Label
4 Iloprost FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7348).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT04166552) A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis. U.S.National Institutes of Health.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 ClinicalTrials.gov (NCT04948554) A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis. U.S.National Institutes of Health.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029522)
11 Deregulated PSGL-1 Expression in B Cells and Dendritic Cells May Be Implicated in Human Systemic Sclerosis Development.J Invest Dermatol. 2018 Oct;138(10):2123-2132. doi: 10.1016/j.jid.2018.04.003. Epub 2018 Apr 22.
12 The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.Clin Appl Thromb Hemost. 2018 Sep;24(6):920-927. doi: 10.1177/1076029617736382. Epub 2017 Nov 12.
13 An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis.Rheumatology (Oxford). 2007 Aug;46(8):1248-51. doi: 10.1093/rheumatology/kem057. Epub 2007 May 23.
14 Attenuation of aquaporin-3 and epidermal growth factor receptor expression and activation in systemic sclerosis dermal fibroblasts.J Cell Physiol. 2019 Aug;234(8):12876-12883. doi: 10.1002/jcp.27952. Epub 2018 Dec 7.
15 Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib.Ann Rheum Dis. 2019 Apr;78(4):539-550. doi: 10.1136/annrheumdis-2018-214382. Epub 2019 Feb 13.
16 Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.Blood Adv. 2018 Jan 23;2(2):126-141. doi: 10.1182/bloodadvances.2017011072.
17 The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.Front Immunol. 2019 Jan 31;10:100. doi: 10.3389/fimmu.2019.00100. eCollection 2019.
18 Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts.Sci Rep. 2019 Mar 14;9(1):4589. doi: 10.1038/s41598-019-39485-8.
19 Fibroblast Growth Factor 23 to Alpha-Klotho Index Correlates with Systemic Sclerosis Activity: A Proposal for Novel Disease Activity Marker.J Clin Med. 2018 Dec 17;7(12):558. doi: 10.3390/jcm7120558.
20 Transcription factor Fra-2 and its emerging role in matrix deposition, proliferation and inflammation in chronic lung diseases.Cell Signal. 2019 Dec;64:109408. doi: 10.1016/j.cellsig.2019.109408. Epub 2019 Aug 29.
21 Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma.Arthritis Rheumatol. 2019 Aug;71(8):1350-1359. doi: 10.1002/art.40890. Epub 2019 Jun 12.
22 Copy Number Variation of HLA-DQA1 and APOBEC3A/3B Contribute to the Susceptibility of Systemic Sclerosis in the Chinese Han Population.J Rheumatol. 2016 May;43(5):880-6. doi: 10.3899/jrheum.150945. Epub 2016 Apr 1.
23 Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.Arthritis Rheumatol. 2018 Jun;70(6):912-919. doi: 10.1002/art.40455.
24 IL-16 expression is increased in the skin and sera of patients with systemic sclerosis.Rheumatology (Oxford). 2020 Mar 1;59(3):519-523. doi: 10.1093/rheumatology/kez318.
25 Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis.Arch Med Sci. 2019 May;15(3):706-712. doi: 10.5114/aoms.2019.84738. Epub 2019 Apr 30.
26 Cross-Disease Innate Gene Signature: Emerging Diversity and Abundance in RA Comparing to SLE and SSc.J Immunol Res. 2019 Jul 16;2019:3575803. doi: 10.1155/2019/3575803. eCollection 2019.
27 Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor and Activate Fibroblasts.Arthritis Rheumatol. 2017 May;69(5):1078-1089. doi: 10.1002/art.40016.
28 Identification of NF-B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis.Arthritis Res Ther. 2015 Mar 21;17(1):71. doi: 10.1186/s13075-015-0572-y.
29 Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts.J Immunol. 2005 Dec 1;175(11):7708-18. doi: 10.4049/jimmunol.175.11.7708.
30 Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis.Clin Exp Immunol. 2010 Jun;160(3):325-30. doi: 10.1111/j.1365-2249.2010.04095.x. Epub 2010 Jan 15.
31 The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis.Clin Rheumatol. 2016 Apr;35(4):919-25. doi: 10.1007/s10067-016-3222-0. Epub 2016 Mar 9.
32 Differential expression of tissue kallikrein in the skin of systemic sclerosis.Histol Histopathol. 2005 Apr;20(2):415-22. doi: 10.14670/HH-20.415.
33 TH17 cellsexpressing CD146 are significantly increased in patients with Systemic sclerosis.Sci Rep. 2019 Nov 27;9(1):17721. doi: 10.1038/s41598-019-54132-y.
34 The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.Mod Rheumatol. 2021 Jan;31(1):151-161. doi: 10.1080/14397595.2019.1704125. Epub 2020 Jan 4.
35 Role of PDGF in fibrotic diseases and systemic sclerosis.Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v2-4. doi: 10.1093/rheumatology/ken265.
36 Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?.Ann Rheum Dis. 2014 Sep;73(9):1700-9. doi: 10.1136/annrheumdis-2013-203706. Epub 2013 Jul 12.
37 Proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic neuropathy in diffuse cutaneous systemic sclerosis: a rare duo.BMJ Case Rep. 2019 Nov 26;12(11):e232987. doi: 10.1136/bcr-2019-232987.
38 Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study.Front Immunol. 2017 Sep 29;8:1242. doi: 10.3389/fimmu.2017.01242. eCollection 2017.
39 Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing GDF6 and SDC2 and provides insight into systemic sclerosis pathogenesis.Ann Rheum Dis. 2015 Jun;74(6):1249-56. doi: 10.1136/annrheumdis-2013-204309. Epub 2014 Jan 17.
40 Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis.Protein Cell. 2015 Aug;6(8):589-598. doi: 10.1007/s13238-015-0171-3. Epub 2015 Jun 20.
41 Extracellular SPARC cooperates with TGF- signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts.Rheumatology (Oxford). 2020 Sep 1;59(9):2258-2263. doi: 10.1093/rheumatology/kez583.
42 Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?.Arthritis Res Ther. 2019 Jun 24;21(1):152. doi: 10.1186/s13075-019-1931-x.
43 Association of TAP1 and TAP2 gene polymorphisms with systemic sclerosis in Korean patients.Hum Immunol. 2005 Jul;66(7):810-7. doi: 10.1016/j.humimm.2005.03.006.
44 The genetics of scleroderma (systemic sclerosis).Curr Opin Rheumatol. 2010 Mar;22(2):133-8. doi: 10.1097/BOR.0b013e3283367c17.
45 TBK1: A key regulator and potential treatment target for interferon positive Sjgren's syndrome, systemic lupus erythematosus and systemic sclerosis.J Autoimmun. 2018 Jul;91:97-102. doi: 10.1016/j.jaut.2018.02.001. Epub 2018 Apr 16.
46 Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3.Arthritis Rheum. 2012 Jan;64(1):272-80. doi: 10.1002/art.30647.
47 Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.
48 Upregulation and pathogenic roles of CCL18-CCR8 axis in IgG4-related disease.Mod Rheumatol. 2020 Jul;30(4):729-737. doi: 10.1080/14397595.2019.1632061. Epub 2019 Aug 8.
49 Depletion of protein kinase Cepsilon in normal and scleroderma lung fibroblasts has opposite effects on tenascin expression.Arthritis Rheum. 2001 Jun;44(6):1370-81. doi: 10.1002/1529-0131(200106)44:6<1370::AID-ART230>3.0.CO;2-2.
50 Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.Arthritis Rheumatol. 2019 Aug;71(8):1339-1349. doi: 10.1002/art.40862. Epub 2019 Jun 18.
51 The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms.Rheumatol Int. 2017 Aug;37(8):1303-1310. doi: 10.1007/s00296-017-3722-5. Epub 2017 Apr 22.
52 Significance of the angiotensin I/angiotensin II/angiotensin-(1-7) axis in the pathogenesis of systemic sclerosis.J Eur Acad Dermatol Venereol. 2020 Mar;34(3):558-564. doi: 10.1111/jdv.16103. Epub 2019 Dec 18.
53 Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.Nat Genet. 2010 May;42(5):426-9. doi: 10.1038/ng.565. Epub 2010 Apr 11.
54 Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC.
55 The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study.Rheumatology (Oxford). 2017 May 1;56(5):844-852. doi: 10.1093/rheumatology/kew499.
56 Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin.Front Immunol. 2018 Oct 1;9:2191. doi: 10.3389/fimmu.2018.02191. eCollection 2018.
57 Clinical relevance of antiphospholipid antibodies in systemic sclerosis: A systematic review and meta-analysis.Semin Arthritis Rheum. 2017 Apr;46(5):615-624. doi: 10.1016/j.semarthrit.2016.10.004. Epub 2016 Oct 13.
58 Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.J Rheumatol. 2003 Jun;30(6):1248-52.
59 Aberrant expression of the innate restriction factor bone marrow stromal antigen-2 in primary Sjgren's syndrome.J Craniomaxillofac Surg. 2018 Nov;46(11):1899-1904. doi: 10.1016/j.jcms.2018.08.008. Epub 2018 Aug 29.
60 Analysis of gene expression patterns in systemic sclerosis fibroblasts using RNA arbitrarily primed-polymerase chain reaction for differential display.J Rheumatol. 2007 Apr;34(4):747-53.
61 CD1a+ survivin+ dendritic cell infiltration in dermal lesions of systemic sclerosis.Arthritis Res Ther. 2015 Sep 30;17:275. doi: 10.1186/s13075-015-0785-0.
62 Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.Arthritis Res Ther. 2018 Oct 3;20(1):223. doi: 10.1186/s13075-018-1719-4.
63 The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjgren's syndrome and systemic sclerosis.Immunol Res. 2017 Jun;65(3):622-629. doi: 10.1007/s12026-016-8880-0.
64 Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.Int J Biochem Cell Biol. 2015 Oct;67:92-100. doi: 10.1016/j.biocel.2015.05.023. Epub 2015 Jun 1.
65 Macrophages and cadherins in fibrosis and systemic sclerosis.Curr Opin Rheumatol. 2019 Nov;31(6):582-588. doi: 10.1097/BOR.0000000000000657.
66 Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers.Respirology. 2019 Jul;24(7):675-683. doi: 10.1111/resp.13500. Epub 2019 Feb 12.
67 The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis.Arthritis Rheum. 1996 Aug;39(8):1355-61. doi: 10.1002/art.1780390813.
68 A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci.Hum Mol Genet. 2013 Oct 1;22(19):4021-9. doi: 10.1093/hmg/ddt248. Epub 2013 Jun 4.
69 A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility.Arthritis Res Ther. 2014 Jan 9;16(1):R6. doi: 10.1186/ar4432.
70 Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014 Jun;349(3):480-6. doi: 10.1124/jpet.114.213520. Epub 2014 Apr 4.
71 Distinct Properties of Human M-CSF and GM-CSF Monocyte-Derived Macrophages to Simulate Pathological Lung Conditions In Vitro: Application to Systemic and Inflammatory Disorders with Pulmonary Involvement.Int J Mol Sci. 2018 Mar 17;19(3):894. doi: 10.3390/ijms19030894.
72 GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y.
73 Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.Rheumatology (Oxford). 2013 May;52(5):790-9. doi: 10.1093/rheumatology/kes379. Epub 2013 Jan 3.
74 Altered B lymphocyte homeostasis and functions in systemic sclerosis.Autoimmun Rev. 2018 Mar;17(3):244-255. doi: 10.1016/j.autrev.2017.10.015. Epub 2018 Jan 16.
75 Decorin is significantly overexpressed in nephrogenic systemic fibrosis.Am J Clin Pathol. 2009 Jul;132(1):139-43. doi: 10.1309/AJCPGB55YDURJXZC.
76 Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts.J Invest Dermatol. 2013 Jan;133(1):110-9. doi: 10.1038/jid.2012.252. Epub 2012 Jul 26.
77 Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data.Front Med (Lausanne). 2018 Jun 6;5:175. doi: 10.3389/fmed.2018.00175. eCollection 2018.
78 ATX-S10(Na)-PDT shows more potent effect on collagen metabolism of human normal and scleroderma dermal fibroblasts than ALA-PDT.Arch Dermatol Res. 2006 Nov;298(6):257-63. doi: 10.1007/s00403-006-0689-6. Epub 2006 Sep 15.
79 Readdressing the entity of exercise pulmonary arterial hypertension.Respir Med. 2017 Mar;124:65-71. doi: 10.1016/j.rmed.2017.02.012. Epub 2017 Feb 17.
80 Increased expression levels of FcRIIB on nave and double-negative memory B cells in patients with systemic sclerosis.Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):23-31. Epub 2019 Jan 17.
81 CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis.Clin Rheumatol. 2017 Jul;36(7):1649-1654. doi: 10.1007/s10067-017-3597-6. Epub 2017 Mar 14.
82 Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts.Arthritis Rheum. 2005 Apr;52(4):1237-47. doi: 10.1002/art.20934.
83 Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis.Arthritis Res Ther. 2019 Jun 7;21(1):143. doi: 10.1186/s13075-019-1912-0.
84 Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function.Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):102-108. Epub 2018 Apr 12.
85 Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis.Clin Rheumatol. 2017 Apr;36(4):853-862. doi: 10.1007/s10067-016-3526-0. Epub 2017 Jan 24.
86 Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome.PLoS One. 2017 Apr 6;12(4):e0175519. doi: 10.1371/journal.pone.0175519. eCollection 2017.
87 [HAX-1 protein: multifunctional factor involved in apoptosis, cell migration, endocytosis and mRNA transport].Postepy Biochem. 2007;53(3):218-27.
88 Upregulation of histidine decarboxylase mRNA expression in scleroderma skin.Arch Dermatol Res. 2001 Apr;293(4):171-7. doi: 10.1007/s004030100206.
89 Acyltransferase skinny hedgehog regulates TGF-dependent fibroblast activation in SSc.Ann Rheum Dis. 2019 Sep;78(9):1269-1273. doi: 10.1136/annrheumdis-2019-215066. Epub 2019 Jun 8.
90 Soluble HLA-G Expression Inversely Correlates With Fetal Microchimerism Levels in Peripheral Blood From Women With Scleroderma.Front Immunol. 2018 Aug 14;9:1685. doi: 10.3389/fimmu.2018.01685. eCollection 2018.
91 Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- signalling to prevent fibrosis.Ann Rheum Dis. 2014 Jun;73(6):1215-22. doi: 10.1136/annrheumdis-2012-203095. Epub 2013 May 9.
92 T follicular helper-like cells contribute to skin fibrosis.Sci Transl Med. 2018 Mar 7;10(431):eaaf5307. doi: 10.1126/scitranslmed.aaf5307.
93 FOXP3, ICOS and ICOSL gene polymorphisms in systemic sclerosis: FOXP3 rs2294020 is associated with disease progression in a female Italian population.Immunobiology. 2018 Jan;223(1):112-117. doi: 10.1016/j.imbio.2017.10.004. Epub 2017 Oct 5.
94 Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic sclerosis: a meta-analysis.Genet Mol Res. 2014 Oct 7;13(4):8174-83. doi: 10.4238/2014.October.7.12.
95 Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.J Immunol. 2016 Jul 1;197(1):42-50. doi: 10.4049/jimmunol.1502190. Epub 2016 May 25.
96 Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis.J Rheumatol. 2008 Nov;35(11):2192-200. doi: 10.3899/jrheum.080418. Epub 2008 Oct 1.
97 Insights into IL-29: Emerging role in inflammatory autoimmune diseases.J Cell Mol Med. 2019 Dec;23(12):7926-7932. doi: 10.1111/jcmm.14697. Epub 2019 Oct 2.
98 IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis.Sci Rep. 2019 Oct 16;9(1):14834. doi: 10.1038/s41598-019-50709-9.
99 Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis.Biochem Biophys Res Commun. 2008 Aug 29;373(3):403-7. doi: 10.1016/j.bbrc.2008.06.054. Epub 2008 Jun 25.
100 Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases.Ann Rheum Dis. 2019 Mar;78(3):311-319. doi: 10.1136/annrheumdis-2018-214127. Epub 2018 Dec 20.
101 IL13RA2 gene polymorphisms are associated with systemic sclerosis.J Rheumatol. 2006 Oct;33(10):2015-9. Epub 2006 Sep 15.
102 Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients.Arthritis Rheum. 2008 Jul 15;59(7):974-83. doi: 10.1002/art.23836.
103 Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis.Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):208-210. Epub 2017 Apr 19.
104 Desmoglein-2-integrin Beta-8 interaction regulates actin assembly in endothelial cells: deregulation in systemic sclerosis.PLoS One. 2013 Jul 11;8(7):e68117. doi: 10.1371/journal.pone.0068117. Print 2013.
105 A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.Arch Dermatol Res. 2017 Dec;309(10):833-842. doi: 10.1007/s00403-017-1786-4. Epub 2017 Oct 16.
106 Long-Term Survival in Bilateral Lung Transplantation for Scleroderma-Related Lung Disease.Ann Thorac Surg. 2018 Mar;105(3):893-900. doi: 10.1016/j.athoracsur.2017.09.038. Epub 2018 Feb 1.
107 Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor -Induced Fibrosis via Binding to v Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.Arthritis Rheumatol. 2019 Feb;71(2):302-314. doi: 10.1002/art.40701. Epub 2019 Jan 4.
108 Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.Ann Rheum Dis. 2017 May;76(5):924-934. doi: 10.1136/annrheumdis-2016-210229. Epub 2017 Jan 6.
109 A novel miRNA-4484 is up-regulated on microarray and associated with increased MMP-21 expression in serum of systemic sclerosis patients.Sci Rep. 2019 Oct 3;9(1):14264. doi: 10.1038/s41598-019-50695-y.
110 Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.Int J Rheum Dis. 2019 Jan;22(1):108-115. doi: 10.1111/1756-185X.13452. Epub 2018 Dec 28.
111 Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population.Sci Rep. 2019 Nov 8;9(1):16366. doi: 10.1038/s41598-019-52920-0.
112 Analysis of the genetic component of systemic sclerosis in Iranian and Turkish populations through a genome-wide association study.Rheumatology (Oxford). 2019 Feb 1;58(2):289-298. doi: 10.1093/rheumatology/key281.
113 Comparison of dextran-based sirolimus-eluting stents and PLA-based sirolimus-eluting stents in vitro and in vivo.J Biomed Mater Res A. 2017 Jan;105(1):301-310. doi: 10.1002/jbm.a.35898. Epub 2016 Oct 31.
114 Physical capacity in performing daily activities is reduced in scleroderma patients with early lung involvement.Clin Respir J. 2017 Jan;11(1):36-42. doi: 10.1111/crj.12299. Epub 2015 May 6.
115 Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I.Arthritis Rheum. 2000 Jul;43(7):1624-32. doi: 10.1002/1529-0131(200007)43:7<1624::AID-ANR28>3.0.CO;2-E.
116 Fox-2 protein regulates the alternative splicing of scleroderma-associated lysyl hydroxylase 2 messenger RNA.Arthritis Rheum. 2010 Apr;62(4):1167-75. doi: 10.1002/art.27315.
117 Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF- signaling.J Dermatol Sci. 2018 May;90(2):199-208. doi: 10.1016/j.jdermsci.2018.02.001. Epub 2018 Feb 6.
118 Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.Ann Rheum Dis. 2018 Mar;77(3):459. doi: 10.1136/annrheumdis-2017-212489. Epub 2018 Jan 8.
119 Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242.
120 PTP4A1 promotes TGF signaling and fibrosis in systemic sclerosis.Nat Commun. 2017 Oct 20;8(1):1060. doi: 10.1038/s41467-017-01168-1.
121 Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis.Ann Rheum Dis. 2018 Nov;77(11):1665-1674. doi: 10.1136/annrheumdis-2018-213239. Epub 2018 Jul 18.
122 Disease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and RORC/FoxP3 Methylation in Systemic Sclerosis.Int Arch Allergy Immunol. 2016;171(2):141-154. doi: 10.1159/000450949. Epub 2016 Dec 1.
123 Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):69-75. Epub 2019 Jul 19.
124 RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase IAntibody-Positive Systemic Sclerosis.J Invest Dermatol. 2017 Sep;137(9):1878-1886. doi: 10.1016/j.jid.2017.04.028. Epub 2017 May 12.
125 High Baseline Serum Clara Cell 16 kDa Predicts Subsequent Lung Disease Worsening in Systemic Sclerosis.J Rheumatol. 2018 Feb;45(2):242-247. doi: 10.3899/jrheum.170440. Epub 2017 Nov 15.
126 Protease nexin-1 messenger RNA levels are not affected by serum or interferon beta in cultured systemic sclerosis fibroblasts.Arch Dermatol Res. 2002 Jan;293(11):584-9. doi: 10.1007/s00403-001-0281-z.
127 Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.Biomed Res Int. 2018 Feb 1;2018:8286067. doi: 10.1155/2018/8286067. eCollection 2018.
128 Evaluation of ITGB2 (CD18) and SELL (CD62L) genes expression and methylation of ITGB2 promoter region in patients with systemic sclerosis.Rheumatol Int. 2018 Mar;38(3):489-498. doi: 10.1007/s00296-017-3915-y. Epub 2018 Jan 22.
129 Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.Blood Coagul Fibrinolysis. 2007 Jun;18(4):297-302. doi: 10.1097/MBC.0b013e328010bd05.
130 Peripheral blood lymphocytes analysis detects CD100/SEMA4D alteration in systemic sclerosis patients.Autoimmunity. 2011 Aug;44(5):427-36. doi: 10.3109/08916934.2010.541171. Epub 2011 Jan 19.
131 Biomarkers of skin and lung fibrosis in systemic sclerosis.Expert Rev Clin Immunol. 2019 Nov;15(11):1215-1223. doi: 10.1080/1744666X.2020.1670062. Epub 2019 Sep 30.
132 Sirtuin1 Protects against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes.Am J Respir Cell Mol Biol. 2018 Jan;58(1):28-39. doi: 10.1165/rcmb.2016-0192OC.
133 Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.Arthritis Rheumatol. 2017 Jun;69(6):1306-1312. doi: 10.1002/art.40065.
134 Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.Arthritis Rheum. 2004 Jan;50(1):216-26. doi: 10.1002/art.11364.
135 Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus.Adv Exp Med Biol. 1999;455:147-52. doi: 10.1007/978-1-4615-4857-7_21.
136 Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts.J Invest Dermatol. 2019 Feb;139(2):439-447. doi: 10.1016/j.jid.2018.08.021. Epub 2018 Sep 28.
137 Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.J Clin Invest. 2004 Jan;113(2):253-64. doi: 10.1172/JCI16269.
138 Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.PLoS Genet. 2011 Jul;7(7):e1002178. doi: 10.1371/journal.pgen.1002178. Epub 2011 Jul 14.
139 Human autoimmune sera as molecular probes for the identification of an autoantigen kinase signaling pathway.J Exp Med. 2002 Nov 4;196(9):1213-25. doi: 10.1084/jem.20021167.
140 Screening and identification of biomarkers for systemic sclerosis via microarray technology.Int J Mol Med. 2019 Nov;44(5):1753-1770. doi: 10.3892/ijmm.2019.4332. Epub 2019 Sep 5.
141 Increased expression of the TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and LTR) in patients with systemic sclerosis.Rheumatology (Oxford). 2019 Mar 1;58(3):502-510. doi: 10.1093/rheumatology/key348.
142 Targeting Costimulatory Pathways in Systemic Sclerosis.Front Immunol. 2018 Dec 18;9:2998. doi: 10.3389/fimmu.2018.02998. eCollection 2018.
143 TCRBV20S1 and TCRBV3S1 gene segment polymorphisms in systemic sclerosis.J Rheumatol. 2008 Jun;35(6):1058-63. Epub 2008 Apr 15.
144 Proangiogenic effects of soluble -Klotho on systemic sclerosis dermal microvascular endothelial cells.Arthritis Res Ther. 2017 Feb 10;19(1):27. doi: 10.1186/s13075-017-1233-0.
145 Association of TRPM Channel Gene Polymorphisms with Systemic Sclerosis.In Vivo. 2015 Nov-Dec;29(6):763-70.
146 Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.Clin Exp Immunol. 2017 Nov;190(2):208-216. doi: 10.1111/cei.13009. Epub 2017 Aug 23.
147 Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.Arthritis Rheumatol. 2016 Aug;68(8):2003-15. doi: 10.1002/art.39658.
148 Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study.Eur Respir J. 2017 Jul 13;50(1):1601708. doi: 10.1183/13993003.01708-2016. Print 2017 Jul.
149 Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis.J Rheumatol. 2012 Jan;39(1):106-11. doi: 10.3899/jrheum.110509. Epub 2011 Nov 1.
150 Significant elevation of IgG anti-WRN (RecQ3 RNA/DNA helicase) antibody in systemic sclerosis.Mod Rheumatol. 2006;16(4):229-34. doi: 10.1007/s10165-006-0496-0.
151 TNFSF14 (LIGHT) Exhibits Inflammatory Activities in Lung Fibroblasts Complementary to IL-13 and TGF-.Front Immunol. 2018 Mar 19;9:576. doi: 10.3389/fimmu.2018.00576. eCollection 2018.
152 Factor VIII related antigen in connective tissue disease patients and relatives.Br J Rheumatol. 1990 Feb;29(1):6-9. doi: 10.1093/rheumatology/29.1.6.
153 NADPH oxidase-mediated induction of reactive oxygen species and extracellular matrix deposition by insulin-like growth factor binding protein-5.Am J Physiol Lung Cell Mol Physiol. 2019 Apr 1;316(4):L644-L655. doi: 10.1152/ajplung.00106.2018. Epub 2019 Feb 27.
154 Association of a rare NOTCH4 coding variant with systemic sclerosis: a family-based whole exome sequencing study.BMC Musculoskelet Disord. 2016 Nov 9;17(1):462. doi: 10.1186/s12891-016-1320-4.
155 Monocytes from Sjgren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis.Clin Exp Immunol. 2014 Sep;177(3):662-70. doi: 10.1111/cei.12378.
156 NRAMP1 (SLC11A1): a plausible candidate gene for systemic sclerosis (SSc) with interstitial lung involvement.J Clin Immunol. 2008 Jan;28(1):73-7. doi: 10.1007/s10875-007-9134-7. Epub 2007 Sep 18.
157 HLA antigens, autoantibodies and clinical subsets in scleroderma.Br J Rheumatol. 1984 Nov;23(4):267-71. doi: 10.1093/rheumatology/23.4.267.
158 Extensive surface phenotyping of alveolar macrophages in interstitial lung disease.Clin Immunol. 2000 Jan;94(1):33-41. doi: 10.1006/clim.1999.4803.
159 Influence of the IL6 gene in susceptibility to systemic sclerosis.J Rheumatol. 2012 Dec;39(12):2294-302. doi: 10.3899/jrheum.120506. Epub 2012 Oct 1.
160 Red cell enzyme types in rheumatic diseases.Hum Hered. 1985;35(2):107-10. doi: 10.1159/000153525.
161 Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans.Arthritis Rheumatol. 2018 Oct;70(10):1654-1660. doi: 10.1002/art.40541. Epub 2018 Aug 29.
162 Effects of thalidomide on Th17, Treg cells and TGF-1/Smad3 pathway in a mouse model of systemic sclerosis.Int J Rheum Dis. 2020 Mar;23(3):406-419. doi: 10.1111/1756-185X.13769. Epub 2019 Dec 16.
163 Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis.Ann Rheum Dis. 2005 Aug;64(8):1165-73. doi: 10.1136/ard.2004.030338.
164 Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype.Autoimmun Rev. 2018 Mar;17(3):267-275. doi: 10.1016/j.autrev.2018.01.006. Epub 2018 Jan 31.
165 Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.Ann Rheum Dis. 2009 Mar;68(3):435-41. doi: 10.1136/ard.2007.086850. Epub 2008 Apr 13.
166 Fibrosin, a novel fibrogenic protein: discovery, cloning and implications for fibrotic disorders.Int Arch Allergy Immunol. 1996 Dec;111(4):326-9. doi: 10.1159/000237388.
167 Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study.Arthritis Res Ther. 2019 Mar 18;21(1):76. doi: 10.1186/s13075-019-1859-1.
168 Scleroderma Patient-centered Intervention Network-Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial.BMJ Open. 2019 Nov 11;9(11):e029935. doi: 10.1136/bmjopen-2019-029935.
169 Association of HLA-DRB1*15:02 and DRB5*01:02 allele with the susceptibility to systemic sclerosis in Thai patients.Rheumatol Int. 2013 Aug;33(8):2069-77. doi: 10.1007/s00296-013-2686-3. Epub 2013 Feb 13.
170 NEMO score in nailfold videocapillaroscopy is a good tool to assess both steady state levels and overtime changes of disease activity in patients with systemic sclerosis: a comparison with the proposed composite indices for this disease status entity.Arthritis Res Ther. 2019 Nov 29;21(1):258. doi: 10.1186/s13075-019-2032-6.
171 Recent advances in animal models of systemic sclerosis.J Dermatol. 2016 Jan;43(1):19-28. doi: 10.1111/1346-8138.13185.
172 Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis.J Immunol Res. 2018 Nov 27;2018:9473243. doi: 10.1155/2018/9473243. eCollection 2018.
173 Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis.Clin Rheumatol. 2018 Sep;37(9):2447-2454. doi: 10.1007/s10067-018-4163-6. Epub 2018 Jun 8.
174 A potential contribution of trappin-2 to the development of vasculopathy in systemic sclerosis.J Eur Acad Dermatol Venereol. 2019 Apr;33(4):753-760. doi: 10.1111/jdv.15387. Epub 2019 Jan 1.
175 PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing.Nat Immunol. 2018 Sep;19(9):942-953. doi: 10.1038/s41590-018-0179-y. Epub 2018 Aug 13.
176 Protective Effect Against Cancer of Antibodies to the LargeSubunits of Both RNA Polymerases I and III in Scleroderma.Arthritis Rheumatol. 2019 Sep;71(9):1571-1579. doi: 10.1002/art.40893. Epub 2019 Aug 1.
177 Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis.Postepy Dermatol Alergol. 2019 Oct;36(5):551-565. doi: 10.5114/ada.2018.79104. Epub 2019 Nov 6.
178 Autoantibodies are present before the clinical diagnosis of systemic sclerosis.PLoS One. 2019 Mar 26;14(3):e0214202. doi: 10.1371/journal.pone.0214202. eCollection 2019.
179 A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis.J Eur Acad Dermatol Venereol. 2018 Feb;32(2):291-297. doi: 10.1111/jdv.14459. Epub 2017 Aug 3.
180 Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis.Arthritis Rheumatol. 2019 Oct;71(10):1711-1722. doi: 10.1002/art.40915. Epub 2019 Aug 27.
181 2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of 2AP in vascular dysfunction in systemic sclerosis.Arthritis Res Ther. 2017 Feb 3;19(1):22. doi: 10.1186/s13075-017-1227-y.
182 Differential upregulation of human 2'5'OAS genes on systemic sclerosis: Detection of increased basal levels of OASL and OAS2 genes through a qPCR based assay.Autoimmunity. 2014 Mar;47(2):119-26. doi: 10.3109/08916934.2013.866102. Epub 2013 Dec 12.
183 46, XX SRY-positive male syndrome presenting with primary hypogonadism in the setting of scleroderma.Endocr Pract. 2011 Jan-Feb;17(1):95-8. doi: 10.4158/EP10184.CR.
184 AIRE gene polymorphisms in systemic sclerosis associated with autoimmune thyroiditis.Clin Immunol. 2007 Jan;122(1):13-7. doi: 10.1016/j.clim.2006.09.013. Epub 2006 Nov 13.
185 Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.Clin Exp Immunol. 1994 May;96(2):267-74. doi: 10.1111/j.1365-2249.1994.tb06552.x.
186 Werner's syndrome: from clinics to genetics.Clin Exp Rheumatol. 2000 Nov-Dec;18(6):760-6.
187 Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro.Clin Immunol. 1999 May;91(2):188-95. doi: 10.1006/clim.1999.4694.
188 B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts.Biochem J. 2004 Mar 1;378(Pt 2):609-16. doi: 10.1042/BJ20031110.
189 Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study.Ann Rheum Dis. 2013 Apr;72(4):602-7. doi: 10.1136/annrheumdis-2012-201888. Epub 2012 Aug 15.
190 Association of the autoimmune disease scleroderma with an immunologic response to cancer.Science. 2014 Jan 10;343(6167):152-7. doi: 10.1126/science.1246886. Epub 2013 Dec 5.
191 Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.Arthritis Res Ther. 2018 May 2;20(1):77. doi: 10.1186/s13075-018-1577-0.
192 Citrullinated vimentin and biglycan protein fingerprints as candidate serological biomarkers for disease activity in systemic sclerosis: a pilot study.Biomarkers. 2019 May;24(3):249-254. doi: 10.1080/1354750X.2018.1548032. Epub 2018 Dec 3.
193 TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients.Arthritis Res Ther. 2017 Jan 19;19(1):8. doi: 10.1186/s13075-016-1213-9.
194 Association study of B-cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis.Clin Exp Rheumatol. 2011 Sep-Oct;29(5):839-42. Epub 2011 Oct 31.
195 The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study.PLoS One. 2015 Feb 6;10(2):e0114856. doi: 10.1371/journal.pone.0114856. eCollection 2015.
196 Identification of the mouse beta'-COP Golgi component as a spermatocyte autoantigen in scleroderma and mapping of its gene Copb2 to mouse chromosome 9.Cytogenet Cell Genet. 1999;87(3-4):201-4. doi: 10.1159/000015467.
197 Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3695-3702. doi: 10.1073/pnas.1813006116. Epub 2019 Feb 12.
198 Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases.Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7267-71. doi: 10.1073/pnas.92.16.7267.
199 Anticentromere antibody-positive primary Sjgren's syndrome: Epitope analysis of a subset of anticentromere antibody-positive patients.Mod Rheumatol. 2017 Jan;27(1):115-121. doi: 10.1080/14397595.2016.1176327. Epub 2016 May 10.
200 Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis Rheumatol. 2019 Jun;71(6):972-982. doi: 10.1002/art.40815. Epub 2019 Apr 26.
201 Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.Ann Rheum Dis. 2014 Oct;73(10):1864-72. doi: 10.1136/annrheumdis-2012-202814. Epub 2013 Jul 19.
202 Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.Ann Rheum Dis. 2019 Sep;78(9):1260-1268. doi: 10.1136/annrheumdis-2019-215119. Epub 2019 May 25.
203 Decreased circulating CXCR3+CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjgren's syndrome to facilitate their concerted migration.Scand J Immunol. 2020 Mar;91(3):e12852. doi: 10.1111/sji.12852. Epub 2019 Dec 13.
204 The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target.Oncotarget. 2017 Dec 20;9(12):10294-10306. doi: 10.18632/oncotarget.23516. eCollection 2018 Feb 13.
205 Myeloid calcium binding proteins: expression in the differentiated HL-60 cells and detection in sera of patients with connective tissue diseases.J Biochem. 1990 Oct;108(4):650-3. doi: 10.1093/oxfordjournals.jbchem.a123257.
206 Inflammatory peeling skin syndrome caused a novel mutation in CDSN.Arch Dermatol Res. 2012 Apr;304(3):251-5. doi: 10.1007/s00403-011-1195-z. Epub 2011 Dec 7.
207 Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population.Clin Chim Acta. 2019 Apr;491:121-125. doi: 10.1016/j.cca.2019.01.020. Epub 2019 Jan 24.
208 Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis.Mod Rheumatol. 2019 May;29(3):476-483. doi: 10.1080/14397595.2018.1480256. Epub 2018 Sep 6.
209 Whole-exome sequencing in a single proband reveals a mutation in the CHST8 gene in autosomal recessive peeling skin syndrome. Genomics. 2012 Apr;99(4):202-8. doi: 10.1016/j.ygeno.2012.01.005. Epub 2012 Jan 25.
210 The Tsk2/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 gene.J Invest Dermatol. 2015 Mar;135(3):718-27. doi: 10.1038/jid.2014.455. Epub 2014 Oct 20.
211 Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations.Adv Clin Exp Med. 2018 Sep;27(9):1253-1257. doi: 10.17219/acem/69921.
212 Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo.Am J Physiol Lung Cell Mol Physiol. 2008 May;294(5):L843-61. doi: 10.1152/ajplung.00295.2007. Epub 2008 Jan 18.
213 Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis.J Dermatol. 2019 Jul;46(7):584-589. doi: 10.1111/1346-8138.14914. Epub 2019 May 14.
214 Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis.J Rheumatol. 2017 Aug;44(8):1198-1205. doi: 10.3899/jrheum.161092. Epub 2017 May 15.
215 Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients.Clin Chim Acta. 2004 Dec;350(1-2):51-5. doi: 10.1016/j.cccn.2004.07.008.
216 Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.Rheumatology (Oxford). 2020 May 1;59(5):1108-1117. doi: 10.1093/rheumatology/kez407.
217 N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor.Front Immunol. 2018 Apr 4;9:574. doi: 10.3389/fimmu.2018.00574. eCollection 2018.
218 Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients.Rheumatology (Oxford). 2006 Jun;45(6):694-702. doi: 10.1093/rheumatology/kei244. Epub 2006 Jan 17.
219 The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis.PLoS One. 2014 Feb 13;9(2):e87754. doi: 10.1371/journal.pone.0087754. eCollection 2014.
220 Oxidative/nitrative stress in the pathogenesis of systemic sclerosis: are antioxidants beneficial?.Free Radic Res. 2018 Oct;52(10):1063-1082. doi: 10.1080/10715762.2018.1525712. Epub 2018 Nov 13.
221 Fibulin-4 is a target of autoimmunity predominantly in patients with osteoarthritis.J Immunol. 2006 Mar 1;176(5):3196-204. doi: 10.4049/jimmunol.176.5.3196.
222 The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor- that is up-regulated in systemic sclerosis and mediates profibrotic responses.Am J Pathol. 2011 May;178(5):2077-90. doi: 10.1016/j.ajpath.2011.01.035.
223 Early growth response 3 (Egr-3) is induced by transforming growth factor- and regulates fibrogenic responses.Am J Pathol. 2013 Oct;183(4):1197-1208. doi: 10.1016/j.ajpath.2013.06.016. Epub 2013 Jul 30.
224 Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.Rheumatology (Oxford). 2018 Apr 1;57(4):712-717. doi: 10.1093/rheumatology/kex458.
225 Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study.Biomed Res Int. 2018 Jul 25;2018:3491798. doi: 10.1155/2018/3491798. eCollection 2018.
226 Human diseases of the SSU processome.Biochim Biophys Acta. 2014 Jun;1842(6):758-64. doi: 10.1016/j.bbadis.2013.11.004. Epub 2013 Nov 12.
227 Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.Am J Kidney Dis. 2019 Feb;73(2):184-193. doi: 10.1053/j.ajkd.2018.05.016. Epub 2018 Aug 16.
228 Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis - report of two cases and review of the literature.Semin Arthritis Rheum. 2020 Jun;50(3):498-502. doi: 10.1016/j.semarthrit.2019.11.008. Epub 2019 Nov 16.
229 Possible single-nucleotide polymorphism loci associated with systemic sclerosis susceptibility: a genetic association study in a Chinese Han population.PLoS One. 2014 Dec 3;9(12):e113197. doi: 10.1371/journal.pone.0113197. eCollection 2014.
230 A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca2+ entry.PLoS One. 2019 Mar 14;14(3):e0213400. doi: 10.1371/journal.pone.0213400. eCollection 2019.
231 U3 snoRNP associates with fibrillarin a component of the scleroderma clumpy nucleolar domain.Arch Dermatol Res. 2002 Oct;294(7):310-7. doi: 10.1007/s00403-002-0338-7. Epub 2002 Sep 5.
232 Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis.J Dermatol. 2017 Oct;44(10):1168-1171. doi: 10.1111/1346-8138.13877. Epub 2017 Apr 22.
233 A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene.Blood. 2019 Apr 25;133(17):1888-1898. doi: 10.1182/blood-2018-10-879585. Epub 2019 Feb 27.
234 Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis.J Dermatol Sci. 2019 Jan;93(1):24-32. doi: 10.1016/j.jdermsci.2018.09.007. Epub 2018 Sep 21.
235 Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability.Arthritis Rheumatol. 2015 May;67(5):1335-44. doi: 10.1002/art.39062.
236 Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors.Arthritis Rheumatol. 2016 Dec;68(12):2975-2985. doi: 10.1002/art.39828.
237 Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis.Exp Dermatol. 2019 Nov;28(11):1313-1320. doi: 10.1111/exd.14033.
238 Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis.Ann Rheum Dis. 2017 Jun;76(6):1150-1158. doi: 10.1136/annrheumdis-2016-210645. Epub 2017 Mar 17.
239 Genomic instability in scleroderma.Asian Pac J Allergy Immunol. 2004 Jun-Sep;22(2-3):153-8.
240 Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts.J Invest Dermatol. 2014 Sep;134(9):2321-2330. doi: 10.1038/jid.2014.69. Epub 2014 Feb 4.
241 Association of DM genes in systemic sclerosis is secondary to the association with HLA genes.Scand J Rheumatol. 1997;26(3):174-9. doi: 10.3109/03009749709065677.
242 Human Leukocyte Antigens-B and -C Loci Associated with Posner-Schlossman Syndrome in a Southern Chinese Population.PLoS One. 2015 Jul 10;10(7):e0132179. doi: 10.1371/journal.pone.0132179. eCollection 2015.
243 Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis Rheumatol. 2016 Jan;68(1):210-7. doi: 10.1002/art.39421.
244 Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti-Interferon-Inducible Protein 16 Antibodies.Arthritis Care Res (Hoboken). 2017 Jun;69(6):922-926. doi: 10.1002/acr.22978.
245 Innate immunity and interferons in the pathogenesis of Sjgren's syndrome.Rheumatology (Oxford). 2021 Jun 18;60(6):2561-2573. doi: 10.1093/rheumatology/key360.
246 Facile fabrication of PEG-coated PLGA microspheres via SPG membrane emulsification for the treatment of scleroderma by ECM degrading enzymes.Colloids Surf B Biointerfaces. 2019 Jul 1;179:453-461. doi: 10.1016/j.colsurfb.2019.04.028. Epub 2019 Apr 14.
247 The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis.Hum Immunol. 2015 Jan;76(1):22-9. doi: 10.1016/j.humimm.2014.12.008. Epub 2014 Dec 11.
248 The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis.Front Immunol. 2019 Sep 13;10:2025. doi: 10.3389/fimmu.2019.02025. eCollection 2019.
249 Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.J Dermatol. 2018 Oct;45(10):1216-1220. doi: 10.1111/1346-8138.14538. Epub 2018 Jul 13.
250 An Allele-Specific Functional SNP Associated with Two Systemic Autoimmune Diseases Modulates IRF5 Expression by Long-Range Chromatin Loop Formation.J Invest Dermatol. 2020 Feb;140(2):348-360.e11. doi: 10.1016/j.jid.2019.06.147. Epub 2019 Aug 15.
251 Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.Ann Rheum Dis. 2019 Nov;78(11):1583-1591. doi: 10.1136/annrheumdis-2019-215208. Epub 2019 Aug 22.
252 Efferocytosis capacities of blood monocyte-derived macrophages in systemic sclerosis.Immunol Cell Biol. 2019 Mar;97(3):340-347. doi: 10.1111/imcb.12217. Epub 2018 Dec 13.
253 The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis.Arthritis Rheum. 2005 Nov;52(11):3618-28. doi: 10.1002/art.21383.
254 Polymorphism of keratin 1 associates with systemic lupus erythematosus and systemic sclerosis in a south Chinese population.PLoS One. 2017 Oct 13;12(10):e0186409. doi: 10.1371/journal.pone.0186409. eCollection 2017.
255 A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis.Exp Dermatol. 2019 May;28(5):536-542. doi: 10.1111/exd.13900.
256 Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts.Arthritis Res Ther. 2014;16(5):411. doi: 10.1186/s13075-014-0411-6.
257 Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidase-like 4: New Evidence From Three-Dimensional Skin-like Tissues.Arthritis Rheumatol. 2020 May;72(5):791-801. doi: 10.1002/art.41163. Epub 2020 Apr 4.
258 Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients.Arthritis Res Ther. 2016 Jan 20;18:20. doi: 10.1186/s13075-016-0923-3.
259 Increased expression of latent TGF--binding protein 4 affects the fibrotic process in scleroderma by TGF-/SMAD signaling.Lab Invest. 2017 May;97(5):591-601. doi: 10.1038/labinvest.2017.20. Epub 2017 Mar 6.
260 Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients.Autoimmun Rev. 2020 Jan;19(1):102431. doi: 10.1016/j.autrev.2019.102431. Epub 2019 Nov 14.
261 Localization of autoepitopes on the PCM-1 autoantigen using scleroderma sera with autoantibodies against the centrosome.Mol Biol Rep. 1998 Mar;25(2):111-9. doi: 10.1023/a:1006814217037.
262 Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis.Scand J Rheumatol. 2009;38(5):369-74. doi: 10.1080/03009740902758875.
263 Systemic sclerosis associated with moyamoya syndrome: A case report and literature review.Immunobiology. 2020 Mar;225(2):151882. doi: 10.1016/j.imbio.2019.11.017. Epub 2019 Nov 28.
264 A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis.PLoS One. 2015 May 8;10(5):e0126015. doi: 10.1371/journal.pone.0126015. eCollection 2015.
265 Semaphorin 4A enhances lung fibrosis through activation of Akt via PlexinD1 receptor.J Biosci. 2015 Dec;40(5):855-62. doi: 10.1007/s12038-015-9566-9.
266 Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera.Clin Immunol Immunopathol. 1997 Apr;83(1):32-40. doi: 10.1006/clin.1996.4322.
267 Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features.Clin Exp Immunol. 2003 Dec;134(3):538-44. doi: 10.1111/j.1365-2249.2003.02320.x.
268 A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression.Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10008-13. doi: 10.1073/pnas.1737765100. Epub 2003 Aug 11.
269 CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts.Arthritis Rheum. 2000 Oct;43(10):2219-29. doi: 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N.
270 Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.Ann Rheum Dis. 2018 Aug;77(8):1208-1218. doi: 10.1136/annrheumdis-2018-213022. Epub 2018 May 14.
271 Molecular Basis for Dysregulated Activation of NKX2-5 in the Vascular Remodeling of Systemic Sclerosis.Arthritis Rheumatol. 2018 Jun;70(6):920-931. doi: 10.1002/art.40419. Epub 2018 Apr 24.
272 Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.Clin Chim Acta. 2017 Sep;472:1-4. doi: 10.1016/j.cca.2017.07.002. Epub 2017 Jul 4.
273 Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.Ann Rheum Dis. 2019 Oct;78(10):1371-1378. doi: 10.1136/annrheumdis-2019-215770. Epub 2019 Aug 7.
274 Chromosome changes in lymphocytes of patients with scleroderma.Ann Genet. 1995;38(3):145-50.
275 De novo truncating variants in PHF21A cause intellectual disability and craniofacial anomalies.Eur J Hum Genet. 2019 Mar;27(3):378-383. doi: 10.1038/s41431-018-0289-x. Epub 2018 Nov 28.
276 Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis.Biochim Biophys Acta. 2006 Jan;1760(1):32-7. doi: 10.1016/j.bbagen.2005.09.001. Epub 2005 Sep 20.
277 Unfolding the pathogenesis of scleroderma through genomics and epigenomics.J Autoimmun. 2017 Sep;83:73-94. doi: 10.1016/j.jaut.2017.05.004. Epub 2017 May 16.
278 Disease-related autoantibody profile in patients with systemic sclerosis.Autoimmunity. 2017 Nov;50(7):414-421. doi: 10.1080/08916934.2017.1357699. Epub 2017 Jul 27.
279 Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis.PLoS Genet. 2011 Jul;7(7):e1002091. doi: 10.1371/journal.pgen.1002091. Epub 2011 Jul 7.
280 Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis.Clin Rheumatol. 2017 Feb;36(2):367-372. doi: 10.1007/s10067-016-3483-7. Epub 2016 Nov 22.
281 A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice.FEBS Open Bio. 2017 Aug 16;7(9):1316-1327. doi: 10.1002/2211-5463.12268. eCollection 2017 Sep.
282 Human leukocyte antigen (HLA)-DRB1 allele polymorphisms and systemic sclerosis.Mod Rheumatol. 2019 Nov;29(6):984-991. doi: 10.1080/14397595.2018.1519148. Epub 2019 Mar 25.
283 Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement.Cytokine. 2019 May;117:41-49. doi: 10.1016/j.cyto.2018.11.013. Epub 2019 Feb 19.
284 RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.J Immunol. 2018 Apr 15;200(8):2777-2785. doi: 10.4049/jimmunol.1701542. Epub 2018 Mar 5.
285 Echocardiographic assessment of regional right ventricular systolic function using two-dimensional strain echocardiography and evaluation of the predictive ability of longitudinal 2D-strain imaging for pulmonary arterial hypertension in systemic sclerosis patients.Int J Cardiovasc Imaging. 2018 Jun;34(6):883-892. doi: 10.1007/s10554-018-1299-z. Epub 2018 Jan 10.
286 Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.Rheumatol Int. 2016 Mar;36(3):421-7. doi: 10.1007/s00296-015-3400-4. Epub 2015 Nov 28.
287 Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype.Rheumatology (Oxford). 2019 Oct 1;58(10):1784-1793. doi: 10.1093/rheumatology/kez123.
288 Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity.Immunogenetics. 2007 Jun;59(6):441-8. doi: 10.1007/s00251-007-0213-y. Epub 2007 Apr 18.
289 A trimetallic CuAuPd nanowire as a multifunctional nanocomposites applied to ultrasensitive electrochemical detection of Sema3E.Biosens Bioelectron. 2019 Dec 1;145:111677. doi: 10.1016/j.bios.2019.111677. Epub 2019 Sep 6.
290 Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease.Rheumatology (Oxford). 2008 Mar;47(3):289-91. doi: 10.1093/rheumatology/kem355. Epub 2008 Feb 8.
291 A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.Arthritis Rheum. 2007 Mar;56(3):1010-20. doi: 10.1002/art.22382.
292 The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor Signaling. Arthritis Rheumatol. 2015 May;67(5):1323-34. doi: 10.1002/art.39061.
293 Asiatic acid prevents the development of interstitial lung disease in a hypochlorous acid-induced mouse model of scleroderma.Oncol Lett. 2018 Jun;15(6):8711-8716. doi: 10.3892/ol.2018.8412. Epub 2018 Apr 2.
294 Is the T-G-CT-G SNRNP70 haplotype another proof that mixed connective tissue disease is distinct from systemic lupus erythematosus and systemic sclerosis? A novel gene variant in SNRNP70 gene.Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):32-40. Epub 2019 Sep 17.
295 Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.Ann Rheum Dis. 2018 Sep;77(9):1326-1332. doi: 10.1136/annrheumdis-2018-213201. Epub 2018 Jun 6.
296 A novel protein highly expressed in testis is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies.J Immunol. 2003 Dec 15;171(12):6883-90. doi: 10.4049/jimmunol.171.12.6883.
297 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.J Med Chem. 2019 May 9;62(9):4350-4369. doi: 10.1021/acs.jmedchem.8b01772. Epub 2019 Apr 18.
298 Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in peripheral blood mononuclear cells in systemic sclerosis.J Rheumatol. 2004 Jan;31(1):88-95.
299 Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis.Clin Immunol. 2013 Oct;149(1):46-54. doi: 10.1016/j.clim.2013.06.006. Epub 2013 Jun 20.
300 Expression of apoptotic and proliferation factors in gastric mucosa of patients with systemic sclerosis correlates with form of the disease.Sci Rep. 2019 Dec 5;9(1):18461. doi: 10.1038/s41598-019-54988-0.
301 MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF- activated kinase 1 binding protein 1, implications for systemic sclerosis.PLoS One. 2014 Dec 30;9(12):e115596. doi: 10.1371/journal.pone.0115596. eCollection 2014.
302 Tribbles homologue 3 stimulates canonical TGF- signalling to regulate fibroblast activation and tissue fibrosis.Ann Rheum Dis. 2016 Mar;75(3):609-16. doi: 10.1136/annrheumdis-2014-206234. Epub 2015 Jan 20.
303 Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure.Mediators Inflamm. 2008;2008:164134. doi: 10.1155/2008/164134. Epub 2009 Jan 25.
304 The expression profile of the toll-like receptor family in scleroderma dermal fibroblasts.Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-4-9. Epub 2014 Jun 6.
305 Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity.Arthritis Rheum. 2012 Aug;64(8):2746-52. doi: 10.1002/art.34490.
306 Male microchimerism in women with systemic sclerosis and healthy women who have never given birth to a son.Ann Rheum Dis. 2005 Jun;64(6):845-8. doi: 10.1136/ard.2004.029314. Epub 2004 Nov 18.
307 Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome.Clin Immunol. 2017 Oct;183:300-303. doi: 10.1016/j.clim.2017.09.012. Epub 2017 Sep 14.
308 Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjgren's syndrome.Rheumatology (Oxford). 2017 Jun 1;56(6):1031-1038. doi: 10.1093/rheumatology/kew501.
309 X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjgren's syndrome.Clin Exp Med. 2017 Feb;17(1):111-119. doi: 10.1007/s10238-015-0404-z. Epub 2015 Dec 11.
310 FcRL4(+) B-cells in salivary glands of primary Sjgren's syndrome patients.J Autoimmun. 2017 Jul;81:90-98. doi: 10.1016/j.jaut.2017.03.012. Epub 2017 Apr 6.
311 Clinical relevance of ROR positive and negative subsets of CD161+CD4+ T cells in primary Sjgren's syndrome.Rheumatology (Oxford). 2017 Feb;56(2):303-312. doi: 10.1093/rheumatology/kew360. Epub 2016 Nov 1.
312 Hypokalaemia in Sjgren's syndrome: the missing piece.Clin Med (Lond). 2017 Feb;17(1):40-42. doi: 10.7861/clinmedicine.17-1-40.
313 The orthologue of Sjgren's syndrome nuclear autoantigen 1 (SSNA1) in Trypanosoma brucei is an immunogenic self-assembling molecule.PLoS One. 2012;7(2):e31842. doi: 10.1371/journal.pone.0031842. Epub 2012 Feb 20.
314 Cardiomyopathy in murine models of systemic sclerosis.Arthritis Rheumatol. 2015 Feb;67(2):508-16. doi: 10.1002/art.38942.